×
D-dimer is a well-established biomarker used primarily as a rule-out test for venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). In patients with low or moderate clinical probability, D-dimer testing helps clinicians safely exclude VTE and reduce unnecessary imaging procedures.
While a negative D-dimer result is highly valuable in clinical decision-making, elevated D-dimer levels are not specific to thrombosis. Increased levels may also be associated with inflammation, infection, trauma, surgery, pregnancy, malignancy, and other clinical conditions. Therefore, D-dimer results should always be interpreted together with clinical evaluation and, when needed, additional diagnostic methods.
In routine practice, D-dimer testing is integrated into broader diagnostic workflows, including coagulation testing, imaging studies, and complementary biomarkers related to inflammation, cardiac injury, and disease severity.
Addressing Complexity in D-dimer Assay Design
D-dimer is generated during the degradation of cross-linked fibrin, reflecting both coagulation activation and fibrinolysis. However, clinical samples contain a heterogeneous mixture of fibrin degradation products (FDPs), including D-dimer-containing fragments of different sizes and structures. This biological complexity creates challenges for assay standardization and performance.
Differences in antibody specificity, epitope recognition, calibrators, and assay formats can lead to variability between D-dimer methods. As a result, D-dimer assays are not fully standardized, and assay-specific cut-offs are required. This variability highlights the importance of carefully selected reagents and assay design to achieve reliable and clinically meaningful results.
Expanding Demand Across Diagnostic Platforms
D-dimer testing is widely used across multiple analytical platforms, including coagulation analyzers, clinical chemistry systems, immunochemistry platforms, and point-of-care testing solutions.
The demand for D-dimer testing continues to grow, driven by the need for efficient diagnostic workflows, rapid clinical decision-making, and the increasing adoption of near-patient testing. As D-dimer applications expand across routine laboratories and decentralized testing environments, assay developers need reliable raw materials that can support robust performance across different platforms.
Hytest Solutions for D-dimer Assay Development
Hytest North America offers a comprehensive portfolio of D-dimer-specific monoclonal antibodies (Cat.# 4D30) and high-purity native D-dimer antigen (Cat. # 8D70) designed to support assay development across diverse diagnostic platforms.
Hytest D-dimer products have been systematically evaluated across multiple assay formats, including:
In evaluated clinical sample sets, selected Hytest antibody pairs have demonstrated strong correlation with commercially available D-dimer assays, supporting their use in the development and optimization of reliable D-dimer assays.
Pair recommendations can be made based on different assay focuses and platform requirements. For customers developing high-sensitivity D-dimer assays, selected antibody pairs support good linearity in the low concentration range of 0.01–0.15 µg/mL and show no detectable cross-reactivity with fibrinogen.
Depending on the intended assay design, antibody pairs can be selected for D-dimer-focused detection, broader FDP/D-dimer-inclusive detection, or platform-specific assay development.
Recommended Antibody(antibodies) for LETIA/TIA Platforms
DD41cc and DD255cc are among the most widely adopted antibody pairs for D-dimer assays on LETIA/TIA platforms.
Recommended Antibody Pair Selection by Assay Focus
Recommended Antibody Pair Selection for CLIA Platforms Based on Correlation with Commercially Available Assays
Recommended Antibody Pair Selection for LF Platforms Based on Correlation with Commercially Available Assays
For details, please contact Hytest North America.
Copyright © Hytest Ltd.